{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.86587","value":"9.9209"},{"groupId":"OG001","spread":"0.00000","value":"0.0000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"170"}],"units":"Participants"}],"title":"Week 8, pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.86542","value":"19.0382"},{"groupId":"OG001","spread":"0.34598","value":"0.0261"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"176"}],"units":"Participants"}],"title":"Week 8, 1-3 hours"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.64363","value":"16.7496"},{"groupId":"OG001","spread":"0.00000","value":"0.0000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"171"}],"units":"Participants"}],"title":"Week 8, 4-6 hours"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.79185","value":"11.0385"},{"groupId":"OG001","spread":"0.03548","value":"0.0039"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"162"}],"units":"Participants"}],"title":"Week 16 pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.19171","value":"11.5167"},{"groupId":"OG001","spread":"0.62447","value":"0.0548"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"130"}],"units":"Participants"}],"title":"Week 24 pre-dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"194"}],"units":"Participants"}],"description":"Blood samples were collected for Pharmacokinetic (PK) analysis in all participants. Three blood samples were collected at Week 8: pre-dose, 1-3 hours post dose, and 4-6 hours post dose. One pre-dose blood sample was obtained at Weeks 16 and 24. Only descriptive analysis performed.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received dabrafenib 150 milligram (mg) HPMC capsules orally twice daily (BID), once in the morning and a second dose approximately 12 hours after the morning dose, and trametinib 2 mg once daily in the morning. Treatment was continued until disease progression, death, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"Dabrafenib + Trametinib"},{"description":"Participants received dabrafenib 150 mg HPMC capsules orally BID, once in the morning and a second dose approximately 12 hours after the morning dose, and trametinib placebo once daily in the morning. Treatment was continued until disease progression, death, unacceptable toxicity, or withdrawal of consent. Crossover to the combination therapy arm was allowed for subjects still receiving study treatment on the dabrafenib monotherapy arm after the positive result for the final OS analysis.","id":"OG001","title":"Dabrafenib + Placebo"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic (PK) Population: all participants included in the safety population for whom a PK sample was obtained and analyzed. Only participants with data available at the specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Week 8 (0, 1-3, 4-6 hours post dose), Weeks 16 and 24 (0 hour pre-dose)","title":"Trametinib Pharmacokinetic Concentrations","type":"SECONDARY","unitOfMeasure":"Nanogram per Milliliter (ng/mL)"}